ETON — Eton Pharmaceuticals, Inc.

Eton Pharmaceuticals, Inc. Q4 2025 Earnings Call Summary

1. Key Financial Results and Metrics:

• Revenue: Q4 2025 product revenue was $21.3 million, an 83% increase year-over-year, driven by strong sales from Alkindi Sprinkle and newly launched products (Incralex, Galzin, and Kindivy).
• Net Income: GAAP net income was $1.5 million, compared to a net loss of $0.6 million in Q4 2024. Non-GAAP net income was $5.4 million.
• Adjusted EBITDA: $6.2 million, representing a 29% margin, up from 18% in the previous year.
• Cash Position: Ended Q4 with $25.9 million in cash, with an operating cash outflow of $11.6 million for the year.

2. Strategic Updates and Business Highlights:

• Product Launches: Successfully launched three new products in 2025, including Desmota, an oral liquid formulation of desmopressin, which addresses a significant unmet need in treating central diabetes insipidus.
• Acquisition of Hemangiol: Acquired for $14 million, expected to enhance Eton's portfolio as it is the only FDA-approved treatment for infantile hemangiomas. The company plans to relaunch it in May 2026.
• Growth in Pediatric Endocrinology: Significant progress in increasing patient awareness and treatment for Incrolex, with over 100 patients now on therapy, and a goal to reach 120 by year-end.
• Market Expansion: Plans to target adult endocrinologists for Desmota, expanding the addressable market beyond pediatric patients.

3. Forward Guidance and Outlook:

• 2026 Revenue Guidance: Expected to exceed $110 million with an adjusted EBITDA margin of at least 30%.
• Long-term Goals: Set new targets to build the largest rare disease portfolio in the U.S., achieve a $200 million revenue run rate by the end of 2027, and reach a 50% adjusted EBITDA margin by 2028.

4. Bad News, Challenges, or Points of Concern:

• Increased Costs: Anticipated rise in SG&A expenses due to FDA program fees and the integration of Hemangiol, projected to increase by approximately $2.8 million in 2026.
• Cash Flow Challenges: Experienced an operating cash outflow in 2025, with significant rebate payments impacting cash flow. However, management expects to return to positive operating cash flow in 2026.
• Market Competition: The company faces competition in the rare disease space and must effectively differentiate its products to capture market share.

5. Notable Q&A Insights:

• Hemangiol Growth Projections: Management expects to significantly increase patient adoption through a zero copay initiative and enhanced marketing efforts.
• Desmota Launch Success: Initial demand for Desmota is strong, with expectations for quicker peak sales compared to previous launches due to existing relationships with pediatric endocrinologists.
• Incralex Payer Discussions: No early payer discussions have occurred regarding potential reimbursements for registry patients, but management remains optimistic about the impact of upcoming studies on sales.

Overall, Eton Pharmaceuticals reported a strong Q4 2025, with significant revenue growth and strategic advancements, while also facing challenges related to cost management and market competition. The company's forward guidance reflects confidence in continued growth and profitability.